Pharmaceutical Technology

MAY 24, 2024

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

Insulin 246

Insulin 246

Bio Pharma Dive

JULY 11, 2022

Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”

Insulin 240

Insulin Manufacturing Production Medicine 240

Bio Pharma Dive

JULY 11, 2024

The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing.

Insulin 189

Insulin Production 189

Pharmaceutical Technology

OCTOBER 12, 2022

Novo Nordisk has recently completed its six-part ONWARDS Phase III trial, as ONWARDS 5 reached its primary endpoint with Icodec demonstrating non-inferiority in reducing hemoglobin A1C (HbA1c) in patients with type 2 diabetes (T2D) at week 52 in comparison to once-daily basal insulin analogs. Patients had an overall baseline HbA1c of 8.9%

Insulin 182

Insulin Trials Marketing FDA Approval 182

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 9, 2022

The most effective way for people with diabetes to deliver insulin is also incredibly intrusive. Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance.

Insulin 203

Insulin Hormones Scientist Clinical Trials 203

Bio Pharma Dive

NOVEMBER 18, 2022

Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

FDA Approval 290

FDA Approval Insulin Drugs 290

Pharmaceutical Technology

MARCH 22, 2024

The EMA CHMP has recommended marketing authorisation for Novo Nordisk's Awiqli for treating diabetes in adult patients.

Insulin 264

Insulin Marketing 264

Pharmaceutical Technology

MARCH 15, 2023

Novo Nordisk has announced plans to reduce the US wholesale acquisition cost (WAC), also known as the list price, of several pre-filled insulin pens and vials by up to 75% for people living with type 1 and type 2 diabetes. Novo Nordisk also has various long-standing US affordability offerings for eligible people who are living with diabetes.

Insulin 147

Insulin Production Branding Marketing 147

Pharmaceutical Technology

MAY 26, 2023

Chronic disease tech company Convatec Group has partnered with Beta Bionics to manufacture the insulin delivery system iLet Bionic Pancrease. According to Beta Bionics, this is the only first and only automated insulin delivery system that carries 100% of doses and does not require carb counting.

Insulin 147

Insulin Manufacturing Pharmacy Marketing 147

Bio Pharma Dive

MARCH 14, 2023

Responding to policy changes and pressure over high drug costs, the pharma is reducing the sticker price of four branded diabetes medicines by up to 75%.

Insulin 299

Insulin Drugs Branding Medicine 299

Pharmaceutical Technology

SEPTEMBER 24, 2024

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

Insulin 312

Insulin 312

Bio Pharma Dive

JANUARY 13, 2023

The state filed suit Thursday against pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, alleging they worked with drugmakers to drive up the price of insulin.

Insulin 147

Insulin Pharmacy 147

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. Insulin rationing. In the US, approximately 37.3

Insulin 130

Insulin Drugs Production Hormones 130

Pharmaceutical Technology

APRIL 18, 2024

At the ongoing Diabetes UK conference, experts highlighted the potential benefits and concerns surrounding weekly insulin candidates.

Insulin 130

Insulin 130

Pharmaceutical Technology

AUGUST 2, 2024

Sanofi has announced a significant investment of €1.3bn ($1.4bn) to expand its insulin production capabilities in Frankfurt, Germany.

Insulin 130

Insulin Production 130

Pharma Times

OCTOBER 11, 2022

Therapy demonstrates significantly accelerated insulin absorption and early exposure

Insulin 142

Insulin Trials 142

Fierce Pharma

APRIL 18, 2024

Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year | Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for (..)

Insulin 133

Insulin Production 133

Pharmaceutical Technology

SEPTEMBER 21, 2023

The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.

Insulin 147

Insulin FDA Approval Marketing 147

NPR Health - Shots

MARCH 19, 2023

Under the $50 million deal, the state is partnering with drugmaker Civica to start making the new generic insulin later this year, Gov. Gavin Newsom said. Image credit: Damian Dovarganes/AP)

Insulin 145

Insulin 145

Bio Pharma Dive

JULY 29, 2021

An injectable insulin from Viatris has become the first-ever biosimilar product that can be directly substituted for a marketed biologic, a long-awaited decision that could put pricing pressure on other diabetes drugs.

FDA Approval 328

FDA Approval Insulin Production Marketing 328

XTalks

OCTOBER 8, 2021

Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks. The medtech giant has also expanded another Class I recall of the retainer rings on its 600 series insulin pumps.

Insulin 128

Insulin Life Science Drugs Regulation 128

Bio Pharma Dive

MARCH 22, 2023

The companies will collaborate to identify compounds that could treat insulin resistance by targeting shape-shifting cellular droplets known as biomolecular condensates.

Insulin 306

Insulin Drugs 306

Bio Pharma Dive

JULY 14, 2021

Rival Novo Nordisk has jumped ahead in developing an injectable drug that responds to changes in blood sugar. An acquisition of Protomer Therapeutics could help Lilly close the gap.

Insulin 299

Insulin Development Drugs 299

Bio Pharma Dive

FEBRUARY 8, 2023

In a State of the Union address, Biden threatened to veto any efforts to repeal the legislation and chastised drugmakers for the current costs of insulin.

Insulin 147

Insulin Drugs 147

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

Bio Pharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Gene Editing 299

Gene Editing Insulin Gene Licensing 299

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

pharmaphorum

JULY 11, 2024

FDA rejects Novo Nordisk’s once-weekly basal insulin for people with diabetes, which would reduce the number of injections needed

Insulin 111

Insulin 111

pharmaphorum

MAY 1, 2024

Polish drug delivery company Biotts says it has demonstrated delivery of insulin across the skin for the first time without the use of an injection system.

Insulin 115

Insulin Drug Delivery Drugs 115

pharmaphorum

JUNE 23, 2024

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 were able to come off insulin within a year

Insulin 115

Insulin 115

Pharmaceutical Technology

JANUARY 10, 2023

In addition, market growth will be driven by dapagliflozin (Farxiga) in the SGLT-2I space, and novel GLP-1/GIP Mounjaro (tirzepatide), biosimilar/interchangeable insulins such as insulin lispro and insulin glargine (Basaglar), and the launch of once-weekly insulins icodec and Icosema, forecast for 2024 launch.

Insulin 130

Insulin Marketing Sales Compliance 130

pharmaphorum

JANUARY 13, 2023

The ‘big three’ insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the state of California for allegedly working together to set artificially inflated prices for their products. The suit follows legal action over insulin pricing taken by other states, including Arkansas , Kansas, Mississippi, and Minnesota.

Insulin 105

Insulin Manufacturing Production Drugs 105

Fierce Pharma

MARCH 22, 2024

. | With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once weekly basal insulin icodec) to the market. It was one of several opinions handed down by the CHMP.

Insulin 128

Insulin Sales Medicine Production 128

Medical Xpress

DECEMBER 12, 2022

WEHI researchers in Melbourne have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill.

Insulin 105

Insulin Research Development 105

pharmaphorum

DECEMBER 11, 2023

How buying Canadian insulin aids Americans without medical coverage Mike.Hammerton Mon, 11/12/2023 - 09:00 Bookmark this

Insulin 118

Insulin 118

BioPharma Reporter

MAY 5, 2022

Oramed Pharmaceuticals announced this week that it has enrolled 100% of the patients in the worldâs first Phase 3 study of oral insulin under FDA approved protocols.

Insulin 112

Insulin Clinical Trials Clinical Trials FDA Approval 112

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 In absolute terms, there were 0.73 events for the once-daily drug.

Insulin 98

Insulin Trials Drugs Production 98